Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Q Wu

Showing results (51-60 of 201) with videos related to

Pageof 21
Sort By:
American Journal of Therapeutics|February 15, 2011
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapyEric Q Wu, Anna Forsythe, Annie Guérin, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2017
Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database AnalysisAmy Guo, Alexander Niyazov, Dendy Macaulay, et al.
Current Medical Research and Opinion|January 26, 2018
The prevalence of hyperkalemia in the United StatesKeith A Betts, J Michael Woolley, Fan Mu, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2014
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysisDaniel J DeAngelo, Lei Chen, Annie Guerin, et al.
Breast Cancer : Basic and Clinical Research|September 19, 2015
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast CancerYan Song, Yanni Hao, Alexander R Macalalad, et al.
Expert Opinion on Pharmacotherapy|August 21, 2015
Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USAPeggy L Lin, Yanni Hao, Jipan Xie, et al.
Clinical Therapeutics|March 8, 2016
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic SitesNanxin Li, Yanni Hao, Jipan Xie, et al.
Rheumatology and Therapy|October 18, 2016
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing SpondylitisKeith A Betts, Jenny Griffith, Yan Song, et al.
Journal of Medical Economics|November 17, 2012
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitorsSaurabh Ray, Vijayveer Bonthapally, Kyle D Holen, et al.
Pharmacoeconomics|July 14, 2012
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsVanja Sikirica, M Haim Erder, Jipan Xie, et al.
Pageof 21

Showing results (51-60 of 201) with videos related to

Sort By:
Pageof 21
American Journal of Therapeutics|February 15, 2011
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapyEric Q Wu, Anna Forsythe, Annie Guérin, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2017
Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database AnalysisAmy Guo, Alexander Niyazov, Dendy Macaulay, et al.
Current Medical Research and Opinion|January 26, 2018
The prevalence of hyperkalemia in the United StatesKeith A Betts, J Michael Woolley, Fan Mu, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2014
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysisDaniel J DeAngelo, Lei Chen, Annie Guerin, et al.
Breast Cancer : Basic and Clinical Research|September 19, 2015
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast CancerYan Song, Yanni Hao, Alexander R Macalalad, et al.
Expert Opinion on Pharmacotherapy|August 21, 2015
Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USAPeggy L Lin, Yanni Hao, Jipan Xie, et al.
Clinical Therapeutics|March 8, 2016
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic SitesNanxin Li, Yanni Hao, Jipan Xie, et al.
Rheumatology and Therapy|October 18, 2016
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing SpondylitisKeith A Betts, Jenny Griffith, Yan Song, et al.
Journal of Medical Economics|November 17, 2012
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitorsSaurabh Ray, Vijayveer Bonthapally, Kyle D Holen, et al.
Pharmacoeconomics|July 14, 2012
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsVanja Sikirica, M Haim Erder, Jipan Xie, et al.
Pageof 21